Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is one of 93 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Jazz Pharmaceuticals PLC to similar companies based on the strength of its profitability, dividends, risk, institutional ownership, earnings, valuation and analyst recommendations.

Insider and Institutional Ownership

88.2% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are owned by company insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Jazz Pharmaceuticals PLC has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals PLC’s competitors have a beta of 1.14, meaning that their average stock price is 14% more volatile than the S&P 500.


This table compares Jazz Pharmaceuticals PLC and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals PLC 25.69% 22.75% 9.14%
Jazz Pharmaceuticals PLC Competitors -917.30% -187.05% -24.43%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Jazz Pharmaceuticals PLC and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals PLC 0 3 16 0 2.84
Jazz Pharmaceuticals PLC Competitors 164 544 1200 16 2.56

Jazz Pharmaceuticals PLC currently has a consensus price target of $182.84, indicating a potential upside of 20.70%. As a group, “Biotechnology” companies have a potential upside of 122.92%. Given Jazz Pharmaceuticals PLC’s competitors higher probable upside, analysts clearly believe Jazz Pharmaceuticals PLC has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Jazz Pharmaceuticals PLC and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Jazz Pharmaceuticals PLC $1.54 billion $758.97 million 23.49
Jazz Pharmaceuticals PLC Competitors $223.74 million $57.84 million -0.73

Jazz Pharmaceuticals PLC has higher revenue and earnings than its competitors. Jazz Pharmaceuticals PLC is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


Jazz Pharmaceuticals PLC beats its competitors on 9 of the 13 factors compared.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.